Physician profile
Alberto Rojas
NPI 1104357839
$5,452.95
in general payments reported to CMS, 2019-2025
17 companies · $255 in 2025
The $255 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,093 · 2020: $1,119 · 2021: $1,456 · 2022: $387 · 2023: $1,123 · 2024: $20.00 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,397.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,029.49 | 2021-2023 | Vraylar |
| Neurocrine Biosciences, INC. | $967.70 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $682.68 | 2019-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $653.86 | 2019-2023 | Uzedy, Austedo |
| Allergan, INC. | $568.86 | 2019-2020 | |
| Alkermes, INC. | $391.12 | 2019-2024 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $291.22 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $246.09 | 2020 | |
| Almatica Pharma LLC | $209.06 | 2022-2025 | Loreev Xr, Sertraline Hcl, Citalopram |
| Biohaven Pharmaceuticals, INC. | $124.99 | 2021 | |
| Sage Therapeutics, LLC | $119.99 | 2020 | |
| Lundbeck LLC | $44.89 | 2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $37.42 | 2020 | |
| Axsome Therapeutics, INC. | $27.59 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $21.09 | 2025 | Invega Sustenna |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $19.73 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $17.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Rojas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.